Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-04 DOI:10.1080/14796694.2025.2502319

Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik

{"title":"Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.","authors":"Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik","doi":"10.1080/14796694.2025.2502319","DOIUrl":null,"url":null,"abstract":"Background: Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics.Materials and methods: Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021.Results: Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (n = 51) and in a subgroup of patients with murine double minute 2 (MDM2) amplification and wild-type tumor protein p53 (TP53 WT) (n = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and MDM2-amplified, TP53 WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the MDM2-amplified, TP53 WT subgroup.Conclusions: The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1797-1807"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150605/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2502319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics.

Materials and methods: Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021.

Results: Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (n = 51) and in a subgroup of patients with murine double minute 2 (MDM2) amplification and wild-type tumor protein p53 (TP53 WT) (n = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and MDM2-amplified, TP53 WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the MDM2-amplified, TP53 WT subgroup.

Conclusions: The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.

查看原文本刊更多论文

美国转移性去分化脂肪肉瘤患者的真实生存结果和MDM2患病率。

背景：关于去分化脂肪肉瘤（DDLPS）治疗、生物标志物频率和临床结果的数据有限。需要更多的流行病学数据来为临床试验设计提供信息，以测试新的治疗方法。材料和方法：对2011年至2021年间接受转移性DDLPS治疗的患者的回顾性数据进行分析，这些数据来自美国的未识别临床基因组数据库。结果：在总队列（n = 51）和小鼠双分钟2 （MDM2）扩增和野生型肿瘤蛋白p53 （TP53 WT）患者亚组（n = 38, 74.5%）中描述了总生存期（OS）、真实无进展生存期（rwPFS）和下一次治疗时间（TTNT）。患者中位年龄为64.8岁，男性占62.7%。最常见的一线治疗是阿霉素联合奥拉拉单抗（23.5%）。从一线（1 L）治疗开始，整个队列和mdm2扩增、TP53 WT亚组的中位总生存期分别为12.6个月和11.7个月；两组的中位rwPFS均为2.5个月。整个队列的中位TTNT为3.9个月，而mdm2扩增TP53 WT亚组的中位TTNT为4.8个月。结论：本文的描述性分析提供了真实世界的数据，描述了DDLPS患者的治疗模式、生物标志物状态和临床结果。DDLPS是一种侵袭性的、特征不明显的LPS，治疗方案有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.